Outlook Therapeutics, Inc. 8-K

What Happened

• Outlook Therapeutics, Inc. (OTLK) filed an 8-K on July 16, 2026 reporting that stockholders approved an amendment to the company’s Restated Certificate of Incorporation to increase authorized common shares from 260,000,000 to 600,000,000. The Certificate of Amendment was filed with the Delaware Secretary of State effective July 16, 2026.
• At a special meeting held that day, holders of 62,303,960 shares (about 51.5% of 120,863,252 shares outstanding as of the record date) were present or represented by proxy and voted on three proposals related to warrants, the authorized-share increase, and a possible reverse stock split.

Key Details

• Authorized shares increased: Amendment filed and effective July 16, 2026 to raise authorized common stock from 260,000,000 to 600,000,000 shares.
  • Vote: For 24,425,476; Against 8,690,115; Abstain 229,586; Broker non-votes 28,958,783.
• Warrants issuance approvals (Proposal 1):
  • Approval for potential issuance of shares underlying Private Placement Warrants to purchase up to 16,129,033 common shares and Placement Agent Warrants to purchase up to 2,258,064 shares.
    • Vote (1a): For 10,132,124; Against 6,556,719; Abstain 527,301; Broker non-votes 28,958,783.
  • Approval for issuance of shares underlying amended previously issued warrants to purchase up to 2,142,854 shares.
    • Vote (1b): For 10,011,424; Against 6,691,578; Abstain 513,142; Broker non-votes 28,958,783.
• Reverse stock split authorized (Proposal 3): Stockholders approved allowing the board to effect a reverse split at a ratio between 1-for-10 and 1-for-50 (board’s discretion).
  • Vote: For 44,271,885; Against 17,765,393; Abstain 266,682.

Why It Matters

• The increase in authorized shares gives the company flexibility to issue additional common stock for financing, strategic transactions, or to satisfy equity awards — which can dilute existing shareholders if and when new shares are issued.
• Approval to potential issuances related to warrants and the large block of broker non-votes reported indicate that future financings tied to the April 2026 registered direct offering and private placement may proceed, subject to other conditions.
• The authorized reverse split (1-for-10 to 1-for-50) gives the board a tool to reduce the number of outstanding shares and potentially raise the per-share price; shareholders should watch for any board action to implement the split and its effective ratio.